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Background: Prostate cancer remains the most common non-skin cancer malignancy in men. Prostate-
speciﬁc antigen (PSA) is recognized as a biomarker for the diagnosis, monitoring, and risk prediction of
prostate cancer. Its use in the setting of prostate cancer screening has been controversial due to the risk
of over diagnosis and over treatment.
Objective: Within Australia, there are inconsistent recommendations surrounding the use of PSA
screening in clinical practice. In light of the 2016 PSA-screening guidelines by the major Australian health
authorities, the current review aims to highlight the controversies and objectively outline the current
recommendations within Australia.
Discussion: Health-care authorities across Australia have issued conﬂicting guidelines for prostate
cancer screening culminating in confusion amongst health care practitioners and members of the public
alike. A general consensus is held by other countries across the globe but differences amongst the speciﬁc
details in how to best employ a PSA screening program still exist.
Copyright © 2016 Asian Paciﬁc Prostate Society, Published by Elsevier. This is an open access article under
the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Prostate cancer (PCa) is the most common cancer diagnosed in
Australian men after non-melanoma skin cancer and accounts for
the second highest number of male cancer deaths.1 PCa differs from
many other cancers as the clinical course is highly variable. Often it
is indolent and may not signiﬁcantly affect overall survival but
conversely, a small subgroup of PCa may represent highly aggres-
sive disease with metastatic potential and may compromise quality
of life and patient survival. Early PCa is asymptomatic, with lower
urinary tract symptoms, hematuria, pelvic pain, and bony pain
representing advanced disease. Accordingly, many men diagnosed
with PCa never know they have the disease unless they are tested.
The rising incidence of PCa has made it an important health
issue. In 2012, there were 3,079 deaths from PCa in Australia and it
was estimated that this ﬁgure would increase to 3,440 deaths inustin Health, Studley Road,
rentschuk).
ciﬁc Prostate Society, Published b2015.2 Over the most recent decade of reports on cancer incidence
in Australia, PCa diagnosis increased from 11,477 in 2000 to 19,993
in 2011. Recently, however, these ﬁgures have been declining with
decreased rates in routine screening. In light of factors such as the
growing Australian population and increasing life expectancy, the
Australian Institute of Health andWelfare predicts that this number
will continue to rise to approximately 25,000 and 31,000 in 2020.3
Prostate-speciﬁc antigen (PSA) is recognized as a biomarker for
the diagnosis, monitoring, and risk prediction of PCa.4e6 PCa
screening is characterized as the systematic examination of
asymptomatic men (at risk) and is initiated by health authorities in
order to reduce mortality and maintain quality of life.7 This is
different to a case-ﬁnding whereby men enter into a process with
their general practitioners (GPs) after discussion on the potential
outcomes of a screening PSA. Routine PSA testing, in conjunction
with digital rectal examination (DRE) are the hallmarks of PCa
screening. To date, PSA screening has aided in the detection of PCa
in millions of men across the world. Globally, the use of total PSA as
a screening tool in the diagnosis of PCa has become a topic of much
debate amongst healthcare governing bodies. Criticism surround-
ing its sensitivity and speciﬁcity proﬁles has prompted carefuly Elsevier. This is an open access article under the CC BY-NC-ND license (http://
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and how it inﬂuences treatment decisionmaking. Similarly, the role
of DRE in screening programs has been a contentious topic in the
guidelines. Subsequently, inconsistent practice has occurred
culminating in signiﬁcant implications for public health.8
1.1. Trends in Australia
Britt et al reported that nearly 778,500 PSA tests were per-
formed in Australia in 2012 with 80% of these tests for men aged
45e74 years. The GP management rate of PCa increased by 57%
from 1998e2000 to 2009e2010, with an estimated 23 to 37 per
10,000 encounters. Similarly, the rate of pathology referrals for PSA
tests increased signiﬁcantly from an estimated 47 per 10,000 en-
counters in 2000e2001 to an estimated 86 per 10,000 encounters
in 2007e2008 (see Fig. 1).9 Increased awareness about the risks of
PCa and the availability of the PSA test among members of the
community may justify this increase in referrals.10 Over the past
decade, the increased number of PSA tests and cases of PCa diag-
nosed may explain the pronounced rate of encounters for the
management of PCa in the GP setting.11
In response to the US preventative task force recommendations
against routine PSA screening in 2008, the number of PSA tests has
fallen in the past few years by up to 35%.12 This has likely ﬂowed on
to a reduction in incidence, although the prevalence of the disease
is stable. The impact of such a reduction creating a cohort of men
presenting at a higher stage and with metastases is yet to be
determined.
2. Controversies of PSA screening for PCa
2.1. Proposed beneﬁts of PSA screening
Early detection of PCa through screening may allow for early
disease stratiﬁcation, prognosis, and treatment prior to disease
progression. Freely available PSA testing in men aged 45e75 years
in Austria conferred a notable shift to lower stages of PCa, as seen in
one of the largest trials in this ﬁeld to date.13 Similarly, data from
the European Randomised Study of Screening for PCa (ERSPC)
Rotterdam section14 revealed a statistically signiﬁcant transition to
improved histological grades and clinical stages on biopsy in the
screening arm compared with the control arm. As such, there is
robust evidence to suggest screening strategies result in earlier
diagnosis of PCa.
The resulting earlier diagnosis and treatment of PCa may pro-
vide men with an oncological beneﬁt. The ERSPC study spanningFig. 1. Trends in prostate-speciﬁc antigen testing.follow-up over 13 years demonstrated a signiﬁcant 21% relative PCa
mortality reduction in favor of screening, and the relative risk
reduction in men actually screened was 27% after adjustment for
selection effects.15 Indeed, the beneﬁt of early treatment for local-
ized PCa was clearly identiﬁed by the Scandinavian Prostate Cancer
Group Trial 4 (SPCG-4). The SPCG-4 trial, which followed up 700
men showed that, at 15 years, the absolute risk reduction of dying
from PCa was 6.1% following randomization to radical prostatec-
tomy compared with watchful waiting.16 These ﬁndings were
maintained at extended follow-up.17 It should be noted that these
ﬁndings are somewhat conﬂicting with those of the Prostate
Intervention Versus Observation Trial (PIVOT), which did not
identify any statistically signiﬁcant difference between the inter-
vention and observation cohorts. However, on subgroup analysis,
all-cause mortality was reduced in men with PSA >10 ng/mL after
radical prostatectomy.18
Improved survival rates were also demonstrated by Roehl
et al19; 7-year progression-free survival rates post-radical prosta-
tectomy were higher in patients who underwent screening,
compared with physician-referred patients (P¼ 0.002). These
beneﬁts do not account for the psychological beneﬁts of a normal
PSA test, especially those with a family history of PCa.
Finally, the impact of PSA testing cannot be ignored. Wherever
PSA testing has been introduced, mortality from PCa has fallen.20,21
Importantly and often not mentioned are the beneﬁts of PSA
screening in reducing presentations of menwith metastatic disease
by around 70%. The morbidity reductions are signiﬁcant as are
reduced costs on the healthcare system. In the same time period,
breast cancer screening has reduced mortality but has had no
impact at all on presentations with metastatic disease.22
2.2. Issues with PSA screening
The risks incurred by PCa screening, diagnosis, and the resulting
treatment are potentially substantial. There is convincing evidence
that PSA-based screening leads to substantial overdiagnosis of
prostate tumors. Overdiagnosis occurs in men in whom PCa would
not have been detected in their lifetime had it not been for
screening, culminating in potentially unnecessary morbidity asso-
ciated to invasive investigations, therapies, and also the mental
implications of the cancer diagnosis.23 The estimated mean lead
time in one study ranged from 5.4 years to 6.9 years, and over-
diagnosis ranged from 23% to 42% of all screening-detected can-
cers.24 The ﬁndings from the G€oteborg screening study similarly
highlighted considerable overdiagnosis in PCa following organized
screening compared to opportunistic PSA testing. This study
concluded that opportunistic screening had minimal effect on the
relative risk reduction in PCa mortality. Furthermore, this group
estimated that almost twice the number of men needed to be
diagnosed to save one man from dying from PCa compared to men
offered an organized 2-yearly PSA screening.25
Findings from the ERSPC trial26 showed that screening increased
PCa incidence by ~80% through the effect of overdiagnosis. In
addition to this, the risk of undergoing radical prostatectomy or
radiation therapy was more than twice as high in the screened
group than in the control group. Approximately 3% of men screened
are diagnosed with aggressive PCa,23 therefore, early detection and
attempted curative therapy can be life-saving. Given that the me-
dian age of PCa death is 80 years, often other causes of mortality
ensue at this time regardless of the PCa detected.27
The beneﬁts of screening were somewhat negated by large-
scale USA data suggesting that PCa screening provided no
reduction in mortality during the ﬁrst 7 years of the trial, with
similar results after 10 years.28 This trial was criticized as the
control arm was contaminated with many patients having PSA
Cabarkapa et al / Prostate cancer screening: Current guidelines 127testing (so really comparing screened with part screened unlikely
to show difference) and has been roundly condemned for it being
given the same weight as the ERSPCda better-conducted trial
lacking contamination.
As a result of active treatment, patients are exposed to the
psychosocial stressors and morbidity. However, the newer practice
of active surveillance for low volume Gleason (3 þ 3¼ 6) in
appropriate patients has helped reduce the implications of
overdiagnosis.29
In addition, issues surrounding PSA levels are widely recognized
and include other possible inﬂuences on PSA levels, which include
prostatitis, urinary tract infection, history of transuretheral resec-
tion, benign prostatic hyperplasia, and recent prostate biopsy.
However, the degree to which these conditions exert an effect on
PSA levels remains unclear.30 It is therefore pertinent for the
clinician and patient to discuss the clinical relevance of PSA levels in
the context of the patient's clinical picture. Furthermore, variation
among PSA measurements between laboratories has been identi-
ﬁed as a limitation to its accuracy as a screening tool. However,
efforts to achieve international standardization of PSA assays exist.2.3. Current guidelines in Australia
As discussed, there are inconsistencies amongst the majority of
current guidelines advocated by healthcare authorities for PCa
screening in Australia. These guidelines are freely available to GPs,
clinicians, and the general public. Conﬂicting recommendations
instill confusion, anxiety, and lack of conﬁdence from the public.31
In Australia, the current published guidelines originate from the
Royal Australasian College of General Practitioners (RACGP), the
Cancer Council of Australia (in conjunction with The Prostate
Cancer Foundation of Australia) and the Royal College of
Pathologists.
The Royal College of Pathologists of Australia recommends that
menwho seek to assess their risk of PCa should be offered a PSA test
and DRE from the age of 40 years as a baseline measure of risk. MenTable 1
Summary of clinical practice guidelines recommendations within Australia.
Routine testing recommendations
Royal College of Pathology Australia
(2016)
Recommended
Prostate Cancer Foundation of
Australia (2016)
Recommended
Cancer Council Australia (2016) Recommended
Urological Society of Australia and
New Zealand (2016)
Recommended
Royal Australian College of General
Practice (2016)
In accordance with PCFA
PCFA, Prostate Cancer Foundation of Australia; PSA, prostate-speciﬁc antigen.with PSA levels above the age-related median should be tested
annually, while those menwith PSA levels below the median could
be tested less frequently. High-risk PSA levels warrant further
investigation with prostate biopsy.32
In January 2016, a new guideline was developed by the Cancer
Council of Australia, in conjunction with The Prostate Cancer
Foundation of Australia (PCFA) based upon data from the National
Health and Medical Research Council (NHMRC). This guideline
involved collaboration between urologists and GPs, as well as many
stakeholders involved in the care of men with PCa. As of May 2016,
the RACGP endorsed the PCFA statement that patients who decide
to undergo regular testing for PCa, should be offered PSA testing
every 2 years from age 50 years to 69 years. Further investigation is
to be offered if the total PSA is > 3.0 ng/mL.33 These recommen-
dations align with the stance of The Urological Society of Australia
and New Zealand.34,35 Furthermore, the RACGP maintain that men
aged 50e69 years (without a family history of PCa) should partake
in informed decision making about PCa screening. The beneﬁts and
harms of prostate screening using the PSA test remain unclear,
therefore, the decision to undergo screening is up to the individual
to request testing from their GP.36 These recommendations are
highlighted in Table 1.2.4. Comparison with international recommendations
The consensus from recommendations from other parts of the
world is geared against a routine test for PCa using a PSA test. In
general, the view that routine PCa testing is not recommended is
held by the American Academy of Family Physicians and The US
Preventive Services Task Force. More speciﬁcally, The American
Urological Association (AUA) recommends against PCa screening
in men aged < 40 years and in men aged  70 years with a life
expectancy of < 10 years. Furthermore, the AUA stance on
asymptomatic men is that the greatest beneﬁt of routine
screening can be found in men aged 55e69 years. Men outside
this age group are encouraged to voice their concerns toEligibility Outlined regime
In men whose life expectancy is
> 7 y
Both a PSA test and a DRE from the
age of 40 y on an annual basis
Men who are at average risk of
prostate cancer who have been
informed of the beneﬁts and
harms of testing, excluding men
aged 70 y
PSA testing every 2 y from age 50 y
to 69 y.
Digital rectal examination is not
recommended as a routine
addition to PSA testing in the
primary care setting
For men at average risk of prostate
cancer who have been informed
of the beneﬁts and harms of
testing and who decide to
undergo regular testing for
prostate cancer
For men aged < 50 y who are
concerned about their risk for
prostate cancer, and have been
informed of the beneﬁts and
harms of testing, and who wish to
undergo regular testing for
prostate cancer, offer testing
every 2 y from age 45 y to age
69 y
DRE is not recommended as a
routine test
In accordance with PCFA
recommendations
PSA every 2 y
Prostate Int 4 (2016) 125e129128healthcare professionals in order to gain the necessary informa-
tion to make an informed and individualized decision. Similarly,
according to the European Association of Urology, mass screening
of PCa is not indicated. However, early diagnosis on an individual
basis is possible based on DRE and PSA testing using a similar
approach to the AUA stance.373. Final recommendations for Australian men and their
health professionals
Menwho have a life expectancy of < 7 years should be informed
thatscreening forPCa isnotbeneﬁcial andhasharmsbecausemanyof
the beneﬁts from screeningmay take > 10 years to ensue. In keeping
with this, the newguidelines state that because anymortality beneﬁt
from early diagnosis of PCa from PSA testing is not seen within < 6
years from testing, PSA testing is not recommended for menwho are
unlikely to live another 7 years. Conversely, men with favorable
prognosis may be considered for surveillance screening protocols
following adequate counseling. Of further relevance is the PSA ve-
locity (PSAV) risk count,which isdeﬁnedas thenumberof serial PSAV
measurements exceeding 0.4 ng/mL/yr. The use of PSAV can signiﬁ-
cantly improve the performance characteristics of screening for
overall PCa and high-grade disease by reducing unnecessary biopsies
and PCa overdiagnosis compared with PSA alone.38
The lowering of the PSA threshold from 4.0 ng/mL to 3.0 ng/mL
has been advocated in previous years. Most recently, the NHMRC
decided on the lower threshold of 3.0 ng/mL. However, the high
false-negative rate associated with this cutoff has real implications
at a population level. Hence, it is probably nowmore appropriate to
refer to age-adjusted and median levels provided on PSA tests to
guide the most appropriate range for any patient. The necessity for
a more ﬂexible approach to threshold values has become apparent
and is reﬂected in the various guidelines. The more recent guide-
lines offer a sensible pathway for testing to the public and their GPs.
The use of PSA as a screening tool should take into account the age
at which screening starts, and the use of different thresholds and
screening intervals to ensure that the lag time to diagnosis and
overtestin” are both minimized.39Conﬂicts of interest
There are no disclosures. The corresponding author is not a
recipient of a scholarship.References
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